MARKET

IBRX

IBRX

Immunitybio Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.355
+0.365
+9.15%
Opening 14:53 07/05 EDT
OPEN
3.960
PREV CLOSE
3.990
HIGH
4.420
LOW
3.830
VOLUME
1.52M
TURNOVER
3.44M
52 WEEK HIGH
13.90
52 WEEK LOW
2.600
MARKET CAP
1.73B
P/E (TTM)
-4.6266
1D
5D
1M
3M
1Y
5Y
ImmunityBio may have saved the day in Dunkirk, but it faces the same challenges as Athenex
The Los Angeles-based company is far different from Athenex, developing different kinds of cancer drugs and building its own business model around those plans, but it also has some notable similarities.
American City Business Journals · 5d ago
TRIP, IBRX and BRZE among after hour movers
Gainers: Kezar Life Sciences (KZR) +99%. Iris Energy (IREN) +5%. Immunity (IBRX) +5%. Cognyte Software (CGNT) +4%. Braze (BRZE) +4%. Losers: Polestar Automotive Holding (PSNYW) -5%. TripAdvisor (TRIP) -4%. Robinhood Market (HOOD)
Seekingalpha · 06/27 21:27
Health authorities push for a vaccine patent waiver to 'genuinely' prepare for the next pandemic
The World Trade Organization is meeting this week to consider adopting an agreement that would make it easier to produce COVID-19 vaccines and treatments by waiving patent enforcement during health emergencies.
Yahoo Finance · 06/14 15:25
ImmunityBio ASCO results show promise for therapies in bladder and pancreatic cancers
Data presented by ImmunityBio (NASDAQ:IBRX) at the American Society for Clinical Oncology Annual Conference showed positive results from two trials in bladder cancer carcinoma and advanced pancreatic cancer. In a
Seekingalpha · 06/06 14:39
ImmunityBio Announces QUILT Trial Results For BCG-Unresponsive Bladder Cancer And Advanced Metastatic Pancreatic Cancer At ASCO 2022
ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting Data from trials underscore
Benzinga · 06/06 13:01
ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
CULVER CITY, Calif., June 06, 2022--ImmunityBio, Inc. (NASDAQ: IBRX), a leading clinical-stage immunotherapy company, today announced new positive data from the company’s pivotal Phase 2/3 trial for BCG-unresponsive non-muscle invasive bladder cancer (NMIB...
Business Wire · 06/06 13:00
--Piper Sandler Adjusts ImmunityBio's Price Target to $10 From $20, Reiterates Overweight Rating
MT Newswires · 05/31 05:33
ImmunityBio files for FDA approval of N-803 BCG combo to treat bladder cancer
ImmunityBio (NASDAQ:IBRX) said it submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of N-803 plus Bacillus Calmette-Guérin (BCG) to treat BCG-unresponsive non-muscle invasive bladder cancer
Seekingalpha · 05/23 13:19
More
No Data
Learn about the latest financial forecast of IBRX. Analyze the recent business situations of Immunitybio Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average IBRX stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.
High10.00
Average10.00
Low10.00
Current 4.355
EPS
Actual
Estimate
-0.21-0.16-0.10-0.05
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 191
Institutional Holdings: 36.77M
% Owned: 9.24%
Shares Outstanding: 397.96M
TypeInstitutionsShares
Increased
44
2.99M
New
30
1.10M
Decreased
39
2.01M
Sold Out
19
926.76K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.98%
Pharmaceuticals & Medical Research
-0.24%
Key Executives
Chairman/Chief Scientific Officer/Executive Director
Patrick Soon-Shiong
President/Chief Executive Officer/Director
Richard Adcock
Chief Financial Officer
David Sachs
Other/Director
Barry Simon
Independent Director
Michael Blaszyk
Independent Director
John Brennan
Independent Director
Wesley Clark
Independent Director
Cheryl Cohen
Independent Director
Linda Maxwell
Independent Director
Christobel Selecky
No Data
No Data
About IBRX
Immunitybio, Inc., formerly NantKwest, Inc., is a late-clinical-stage immunotherapy company developing therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The Company’s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T-cell) immune systems to create long-term immunological memory. The Company is engaged in developing molecular and product platforms based on three key modalities: activating NK and T cells using antibody cytokine fusion proteins, activating tumoricidal macrophages using low-dose synthetic immunomodulators, and generating memory T cells using vaccine candidates developed with second-generation adenovirus (hAd5) technology. It is also developing therapies, including vaccines, for the prevention and treatment of human immunodeficiency virus (HIV), influenza, and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with its human adenovirus (hAd5) vaccine technologies.

Webull offers kinds of Immunitybio Inc stock information, including NASDAQ:IBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IBRX stock methods without spending real money on the virtual paper trading platform.